Compare DOCS & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOCS | ELVN |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 4.2B |
| IPO Year | 2021 | 2020 |
| Metric | DOCS | ELVN |
|---|---|---|
| Price | $25.81 | $53.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 5 |
| Target Price | ★ $45.50 | $43.40 |
| AVG Volume (30 Days) | ★ 2.4M | 809.9K |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.17 |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $644,863,000.00 | N/A |
| Revenue This Year | $15.08 | N/A |
| Revenue Next Year | $8.83 | N/A |
| P/E Ratio | $196.77 | ★ N/A |
| Revenue Growth | ★ 13.05 | N/A |
| 52 Week Low | $17.15 | $14.79 |
| 52 Week High | $76.51 | $62.32 |
| Indicator | DOCS | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 57.59 | 36.37 |
| Support Level | $23.46 | $25.63 |
| Resistance Level | $27.03 | $62.16 |
| Average True Range (ATR) | 0.92 | 2.02 |
| MACD | -0.17 | -0.84 |
| Stochastic Oscillator | 72.36 | 5.32 |
Doximity Inc provides an online platform, which enables physicians and other healthcare professionals to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. The Company's customers include pharmaceutical companies and health systems that connect with healthcare professionals through the Company's digital Marketing, Hiring, and Workflow Solutions. Marketing Solutions provide customers with the ability to share tailored content on the network. Hiring Solutions enable customers to identify, connect with, and hire from the network of both active and passive potential medical professional candidates.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.